These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28179196)

  • 41. [Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].
    Xu H; Wang KQ; Huang WW; Deng YH; Chen DW
    Yao Xue Xue Bao; 2010 Jun; 45(6):677-83. PubMed ID: 20939173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A higher dose of PEGylated gold nanoparticles reduces the accelerated blood clearance phenomenon effect and induces spleen B lymphocytes in albino mice.
    Abu-Dief AM; Alsehli M; Awaad A
    Histochem Cell Biol; 2022 Jun; 157(6):641-656. PubMed ID: 35157114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.
    Ishida T; Ichihara M; Wang X; Yamamoto K; Kimura J; Majima E; Kiwada H
    J Control Release; 2006 May; 112(1):15-25. PubMed ID: 16515818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
    Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
    J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats.
    Wang XY; Ishida T; Ichihara M; Kiwada H
    J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
    Shiraishi K; Kawano K; Maitani Y; Aoshi T; Ishii KJ; Sanada Y; Mochizuki S; Sakurai K; Yokoyama M
    J Control Release; 2016 Jul; 234():59-67. PubMed ID: 27164541
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
    Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
    Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
    Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.
    Alaaeldin E; Abu Lila AS; Moriyoshi N; Sarhan HA; Ishida T; Khaled KA; Kiwada H
    Pharm Res; 2013 Sep; 30(9):2344-54. PubMed ID: 23673556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens.
    Ando H; Abu Lila AS; Kawanishi M; Shimizu T; Okuhira K; Ishima Y; Ishida T
    J Control Release; 2018 Jan; 270():114-119. PubMed ID: 29217175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice.
    Emam SE; Elsadek NE; Abu Lila AS; Takata H; Kawaguchi Y; Shimizu T; Ando H; Ishima Y; Ishida T
    J Control Release; 2021 Jun; 334():327-334. PubMed ID: 33957196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA.
    Tagami T; Uehara Y; Moriyoshi N; Ishida T; Kiwada H
    J Control Release; 2011 Apr; 151(2):149-54. PubMed ID: 21223988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.
    Ishida T; Harada M; Wang XY; Ichihara M; Irimura K; Kiwada H
    J Control Release; 2005 Jul; 105(3):305-17. PubMed ID: 15908032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery.
    Ichihara M; Moriyoshi N; Lila AS; Ishida T; Kiwada H
    Methods Mol Biol; 2013; 948():35-47. PubMed ID: 23070762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy.
    Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y
    Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats.
    Ichihara M; Shimizu T; Imoto A; Hashiguchi Y; Uehara Y; Ishida T; Kiwada H
    Pharmaceutics; 2010 Dec; 3(1):1-11. PubMed ID: 24310423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
    Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
    Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-polyethyleneglycol antibody response to PEGylated substances.
    Ishida T; Kiwada H
    Biol Pharm Bull; 2013; 36(6):889-91. PubMed ID: 23727911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.